FGF-1 vs Sigumir

Binds all four FGFR subtypes (broadest binding of FGF family). Activates MAPK and PI3K downstream pathways. Promotes fibroblast proliferation, angiogenesis, and hair follicle cycling into anagen phase.

FGF-1 (fibroblast growth factor 1; acidic FGF; aFGF) is an endogenous 155-amino-acid heparin-binding growth factor and the prototypic member of the 22-member FGF family, expressed in diverse tissues where it stimulates cell proliferation, survival, and migration through tyrosine kinase receptor (FGFR1-4) signaling, with particularly important roles in angiogenesis, wound healing, and tissue repair. FGF-1 activates FGFR to initiate MAPK/ERK, PI3K/Akt, and PLCgamma signaling cascades driving endothelial cell sprouting and neovascularization; in ischemic tissues, FGF-1 is a potent inducer of therapeutic angiogenesis, stimulating new vessel formation to restore perfusion in peripheral arterial disease and critical limb ischemia. A Phase 2 randomized controlled trial of intramuscular gene-encoded FGF-1 delivery (NV1FGF, a non-viral plasmid vector) in critical limb ischemia demonstrated improved amputation-free survival in human subjects, providing clinical evidence for FGF-1 pathway activity; this gene therapy approach is distinct from direct recombinant FGF-1 protein administration, and no protein therapy form has completed Phase 3 trials. Recombinant FGF-1 protein has no FDA approval as a standalone therapeutic; the clinical evidence base references gene-encoded delivery rather than the protein itself, and research-grade FGF-1 is used primarily as a cell culture supplement and tissue engineering scaffold factor rather than as a therapeutically administered agent.

Tetrapeptide bioregulator targeting joint and bone tissue; modulates osteoblast and chondrocyte activity; reduces local joint inflammation; promotes extracellular matrix production

Sigumir is a Khavinson-class short bioregulator peptide investigated for joint, cartilage, and connective tissue support. Like other ultrashort peptides in this research category, sigumir is proposed to reach musculoskeletal target tissues via amino acid transporter mechanisms and modulate gene expression in aging musculoskeletal cells. Published research on related Khavinson bioregulator peptides documents transport feasibility across biological membranes and broad gene expression regulatory effects in preclinical aging models. Human clinical data specific to sigumir is sparse; evidence is based on class-level mechanistic and preclinical research rather than direct sigumir-specific trials. Sigumir dosing and research context Sigumir is typically formulated as an oral capsule or sublingual peptide bioregulator in the Khavinson research tradition, with protocols in the preclinical literature referencing cycles of 10–20 days at low doses (in the range of 5–10mg per cycle, divided daily), followed by rest intervals. This intermittent dosing pattern is characteristic of the Khavinson bioregulator peptide class — the proposed mechanism involves gene expression modulation in target tissue cells rather than continuous receptor occupancy, which is argued to support pulse-dosing protocols. Sigumir's proposed target tissue is articular cartilage and connective tissue, distinguishing it from other Khavinson peptides that target specific organ systems (e.g., Testagen for testicular tissue, Thymalin for thymic tissue). Available through specialty peptide vendors and some Eastern European pharmacy channels as a research or supplement product; not available as a prescription medication in Western markets and not FDA-reviewed.